Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
|
| gptkbp:affiliatedWith |
glycopeptide antibiotics
|
| gptkbp:approvedBy |
1958
|
| gptkbp:ATCCode |
J01XA01
|
| gptkbp:brand |
vancomycin
|
| gptkbp:chemicalFormula |
C66H75Cl2N9O24
|
| gptkbp:contraindication |
hypersensitivity to vancomycin
|
| gptkbp:eliminationHalfLife |
4-6 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vancocin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
gptkb:red_man_syndrome
nephrotoxicity ototoxicity |
| gptkbp:usedFor |
gptkb:Clostridioides_difficile_infection
methicillin-resistant Staphylococcus aureus (MRSA) infections treatment of serious bacterial infections |
| gptkbp:bfsParent |
gptkb:Vancomycin
|
| gptkbp:bfsLayer |
5
|